Eton Pharmaceuticals

NASDAQ: ETON ↗$45.80 USD~$1.0B (small/mid-cap commercial-stage, July 2026) MCAP

#Rare Disease Therapeutics #Pediatric Endocrinology #Hyperammonemia #Specialty Hospital Injectables #Metabolic Disorders

Eton Pharmaceuticals is a commercial-stage specialty pharmaceutical company developing, acquiring, and commercializing high-potential therapies for the treatment of rare diseases. The company's commercial portfolio includes Alkindi Sprinkle (hydrocortisone pediatric granules), Carglumic Acid (N-carbamylglutamate for hyperammonemia), Rezipres (ephedrine injection), and Betaine Anhydrous. Eton also operates a royalty-monetization business that has provided non-dilutive capital to fund late-stage clinical assets in-licensed from larger developers. In July 2026, Canaccord Genuity raised its price target on Eton to $60, citing accelerating rare-disease commercial momentum.

Company Info

Sector:Pharmaceuticals / Rare Disease

Headquarters:Deer Park, Illinois, USA

Founded:2017

Website:ir.etonpharma.com/

Upcoming Milestones & Key Dates

Q2 2026 earnings

Corporate

Q2 2026 financial results expected August 2026

Clinical Development Pipeline

Alkindi Sprinkle

Target: Granule formulation of hydrocortisone for pediatric dosing flexibility

Pediatric adrenal insufficiency (hydrocortisone replacement)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Carglumic Acid

Target: Carglumic acid (N-carbamylglutamate)

N-acetylglutamate synthase deficiency (NAGS deficiency) and organic acidemia hyperammonemia

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Rezipres

Target: Ephedrine hydrochloride injection

Acute hypotension in surgical settings

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Betaine Anhydrous

Target: Betaine anhydrous oral solution

Homocystinuria

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Sean E. Brynjelsen

President, Chief Executive Officer and Director

Careers & Job Openings

See all open roles

Multiple Departments

Deer Park, IL

Apply Now →